Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Still hard to know how large the benefits will really be
| The first 150 words of the full text of this article appear below. |
Ever since the implementation of the NHS breast
screening programme in 1988 two important questions have been
consistently raised. Should the age range of women invited be extended
from the current range of 50-64 years, and should the screening
interval be reduced from the current three years? If we are to believe
the cost effectiveness analysis by Boer et al in this week's issue (p
376),1 an increase in age to 69 and a two year interval
would each generate substantial benefits in life years saved and deaths
averted
but, needless to say, at a substantial cost. Moreover, the
authors' conclusion that extending the age range is expected to
prevent more deaths, whereas shortening the screening interval would
save more life years leaves policymakers with a
not
unfamiliar
ethical dilemma.
It is obviously desirable to improve life expectancy in those women
already eligible for screening. Reducing the interval cancer rate,
which is particularly high
Read all Rapid Responses